CEO Olivier Rousseau Outlines SGD Pharma’s Vision for 2024, Focusing on Global Expansion and Strategic Investments
SGD Pharma, a powerhouse in the pharmaceutical glass packaging industry, has set the stage for an ambitious growth trajectory in 2024, aiming to cement its status as the undisputed global leader in primary pharmaceutical glass packaging. As the pharmaceutical landscape evolves, SGD Pharma, under the strategic guidance of CEO Olivier Rousseau, is poised to make significant strides, building on the momentum gained in the preceding year.
In the dynamic and competitive realm of pharmaceutical packaging, SGD Pharma made headlines in 2023 with a groundbreaking partnership announcement. The company entered into a joint venture with Corning, backed by investment from the Telangana state in India. This strategic collaboration seamlessly merged Corning’s cutting-edge coating technology with SGD Pharma’s expertise in glass conversion. The result: Velocity Vials, a groundbreaking product crafted from Type I borosilicate glass tubing.
The symbolic initiation of this venture was marked by a celebratory ground-breaking ceremony at the new tubing plant in Vemula, India, in June 2023. This facility, upon completion, will not only bolster pharmaceutical packaging manufacturing in India but also serve as a regional hub for the Corning Velocity Vial technology.
But SGD Pharma’s vision extends beyond innovation; sustainability and decarbonization form integral components of their corporate ethos. In 2023, the company achieved a gold EcoVadis sustainability rating, a testament to its commitment to environmentally responsible practices. Several modifications were implemented throughout the year to enhance their sustainability profile, setting the stage for continued excellence in this domain.
The investment landscape also witnessed notable developments. Apart from the new line in Vemula, India, SGD Pharma directed attention to its Saint Quentin Lamotte (SQLM) plant in France, where the renovation of one of two furnaces took place. Additionally, a Memorandum of Understanding was inked with the Mayor of Zhanjiang, China, outlining plans for SGD Pharma’s investment in the furnace reconstruction at Zhanjiang. To enhance flexibility and capacity, a new siliconization operation line is set to become operational at the SQLM plant.
Product-wise, SGD Pharma introduced the extension of its Clareo range, now featuring a 10ml variant, along with the Sterinity range of ready-to-use vials in sizes 10ml and 20ml. The latter part of the year witnessed the announcement of the pharmaceutical vial thermosealing offering, PROSEAL+.
Celebrating a significant milestone, SGD Pharma marked 30 years in China at its Zhanjiang manufacturing plant, a facility renowned for producing molded glass and holding the market leader position in glass for cosmetics and beauty packaging.
As SGD Pharma looks ahead to 2024, CEO Olivier Rousseau anticipates a series of strategic unveilings, with the initial revelations scheduled for Pharmapack 2024 at booth B60/B62. These developments are expected to further solidify SGD Pharma’s standing as an industry trailblazer, driving innovation, sustainability, and growth.
Source: SGD Pharma with additional information added by Apazone